David A. Siegel Immatics N.V. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Immatics N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 18,700 shares of IMTX stock, worth $100,419. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,700

Previous 59,800 68.73%

Holding current value

$100,419

Previous $682,000 80.65%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$6.73 - $11.21 $276,603 - $460,731	-41,100 Reduced 68.73%	18,700 $132,000
Q3 2024 Nov 14, 2024	SELL	$10.93 - $12.92 $442,665 - $523,260	-40,500 Reduced 40.38%	59,800 $682,000
Q2 2024 Aug 14, 2024	SELL	$9.78 - $13.49 $559,416 - $771,628	-57,200 Reduced 36.32%	100,300 $1.17 Million
Q1 2024 May 15, 2024	BUY	$10.23 - $12.94 $201,531 - $254,918	19,700 Added 14.3%	157,500 $1.66 Million
Q4 2023 Feb 14, 2024	BUY	$7.36 - $10.89 $811,506 - $1.2 Million	110,259 Added 400.34%	137,800 $1.45 Million
Q3 2023 Nov 14, 2023	SELL	$11.01 - $12.62 $77,719 - $89,084	-7,059 Reduced 20.4%	27,541 $318,000
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $82,288 - $176,808	13,900 Added 67.15%	34,600 $399,000
Q1 2023 May 15, 2023	SELL	$6.74 - $9.44 $125,364 - $175,584	-18,600 Reduced 47.33%	20,700 $142,000
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $166,635 - $239,706	20,700 Added 111.29%	39,300 $342,000
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $61,566 - $242,916	18,600 New	18,600 $186,000
Q2 2022 Aug 15, 2022	SELL	$6.0 - $9.37 $67,800 - $105,880	-11,300 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$6.64 - $12.85 $1,992 - $3,855	-300 Reduced 2.59%	11,300 $90,000
Q4 2021 Feb 14, 2022	SELL	$10.81 - $14.38 $3,243 - $4,314	-300 Reduced 2.52%	11,600 $156,000
Q3 2021 Nov 15, 2021	SELL	$11.58 - $15.46 $30,108 - $40,196	-2,600 Reduced 17.93%	11,900 $155,000
Q2 2021 Aug 16, 2021	BUY	$10.43 - $12.81 $35,462 - $43,554	3,400 Added 30.63%	14,500 $168,000
Q1 2021 May 17, 2021	SELL	$10.24 - $14.6 $51,200 - $73,000	-5,000 Reduced 31.06%	11,100 $124,000
Q4 2020 Feb 16, 2021	SELL	$9.67 - $12.05 $29,977 - $37,355	-3,100 Reduced 16.15%	16,100 $174,000
Q3 2020 Nov 16, 2020	BUY	$8.73 - $15.15 $167,616 - $290,880	19,200 New	19,200 $204,000

Others Institutions Holding IMTX

# of Institutions

Shares Held

92.5M

Call Options Held

313K

Put Options Held

377K

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $409M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account